focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-GoDaddy, Twitter, Pier 1, Michael Kors

Wed, 01st Apr 2015 16:27

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stocks dipped at the open on Wednesday as aweaker-than-expected report on private sector employment raisedconcerns that Friday's impending jobs report could also point toworsening conditions in the labor market.

The Dow Jones industrial average was down 0.60percent at 17,669.26, the S&P 500 was down 0.56 percentat 2,056.36 and the Nasdaq Composite was down 0.77percent at 4,862.98.

** GODADDY INC, $26.25, +31.25 pct

The web hosting company's shares rose as much as 34 percentin their debut, valuing the firm at about $5.48 billion,including debt. The company raised $460 million after itsinitial public offering of 23 million class A shares was pricedat $20 per share, above the expected range of $17-$19.

** ON SEMICONDUCTOR CORP, $11.2, -7.51 pct

Goldman Sachs downgraded the power management chip maker'sstock to "sell" from "neutral" and cut its price target to$10.50 from $12.50. The appreciation of the dollar will driveON's European and Asian competitors to be more aggressive onpricing, and data shows that pricing declines intensify when thedollar strengthens, Goldamn analysts wrote.

** TWITTER INC, $50.95, +1.74 pct

Jefferies & Co started coverage of the microblogging serviceprovider's stock with a "buy" rating and price target of $65.Twitter is "well positioned" to benefit from online videoadvertising and mobile tailwinds, Jefferies analysts said.

** PIER 1 IMPORTS INC, $13.16, -5.87 pct

Analysts at Morgan Stanley downgraded the furnitureretailer's stock to "underweight" from "equal-weight" and cuttheir target price to $11 from $13, saying sales at Pier 1'sretail business are expected to decline in the low single digitpercentage range, partly due to store volumes being cannibalizedby e-commerce sales.

** HONG KONG TELEVISION NETWORK LTD, $7.42, -22.47pct

The video production and distribution company said onTuesday that it had not agreed on a possible transaction withAsia Television Ltd (ATV). Seeking Alpha, citing media reports,also said on Tuesday that Hong Kong TV's Executive Chairman WongWai Kay was buying a controlling stake in nearly bankrupt rivalATV.

** ACHAOGEN INC, $7.81, -19.98 pct

The drug developer said it is planning an additionallate-stage trial of its lead drug to treat complicated urinarytract infections, and the U.S. FDA agreed to change the trialprotocol, which Achaogen believes will improve theslower-than-expected patient enrollment rate in the existingtrial. Needham & Co analysts, however, said the changes willmean a more modest initial sales ramp and cut the target priceon the stock by $6 to $15.

** TREVENA INC, $7.28, +11.66 pct

Wedbush Securities started covering the drug developer'sstock with an "outperform" rating and a $15 price target.Analysts said the company's drug for acute heart failure, whichis being tested in mid-stage studies, is "set up for success",and that Actavis Plc will exercise its option for theprogram if the study is successful.

** MICHAEL KORS HOLDINGS LTD, $64.3, -2.21 pct

Analysts at Piper Jaffray cut their rating on the luxuryaccessories retailer's stock to "neutral" from "overweight" andcut their price target to $70 from $89, saying they werecautious about North American same-store sales growth over next6-12 months. North America same-store sales growth slowed to 6percent in the three months ended Dec. 27, falling below 10 pctfor the first time.

** SOLAR3D INC, $5.3202, +6.40 pct

The solar cell developer reported a full-year adjustedprofit, compared with a loss a year earlier.

** FORD MOTOR CO, $15.86, -1.73 pct

** GENERAL MOTORS CO, $36.825, -1.80 pct

** FIAT CHRYSLER, $16.22, -0.55 pct

U.S. consumer demand for new vehicles began to thaw in Marchwith Detroit automakers reporting mixed sales results. FordMotor's U.S. sales fell 3.4 pecrent, while General Motorsreported a 2.4 pecrent fall, and Fiat Chrysler sales grew 2pecrent.

** EURONAV NV, $12.6, +4.48 pct

The tanker company proposed a gross dividend of 25 cents pershare in view of strong tanker markets. The company also plansto distribute at least 80 pct of its "annual net result" forfuture dividends as part of new dividend policy.

** EXCO RESOURCES INC, $2, +9.29 pct

The oil and gas producer named Chief Financial OfficerHarold Hickey chief executive, and said Bluescape Resources CoLLC, an investment firm focused on the oil and gas industry,would buy $10 million of EXCO's shares and an additional $40million in shares on the open market within one year fromclosing. EXCO and Bluescape will work on executing restructuringcommercial contracts and JVs, and increase focus on reducingcosts.

** ENERGY RECOVERY INC, $2.96, +14.29 pct

The energy recovery devices maker said it had received itslargest project to date in the oil and gas industry. SaudiAramco's gas processing plant will become the first to useEnergy Recovery's IsoGen system, a turbogenerator that recyclesotherwise wasted pressure energy and converts it into electricalpower.

** IMMUNE DESIGN CORP, $26.26, +24.40 pct

Analysts at Jefferies & Co upgraded the drug developer'sstock to "buy" after it reported positive data from early-stagestudies of its experimental cancer compounds. Immune Design onTuesday said results from three early studies showed that itstwo primary cancer drugs were safe and showed signs of efficacy.

** CAMPUS CREST COMMUNITIES INC, $6.46, -9.78 pct

The owner and manager of student housing properties said itdoes not anticipate declaring any dividend payments for 2015.The company also suspended the dividend payment on its series Acumulative redeemable preferred shares.

** NYMOX PHARMACEUTICAL CORP, $1.2899, +53.56 pct

The drug developer said it would undertake further analysesof its failed pivotal U.S. late-stage studies, including newlong-term data, of its drug, NX-1207. The company also said itexpects to provide new pivotal late-stage study results in thesecond-quarter or early in the third-quarter.

** WAL-MART STORES INC, $80.6, -2.01 pct

The world's largest retailer is looking at how it sourcesits products, especially considering falling commodity pricesglobally, in an effort to reduce its prices, the head of theretailer's U.S. division said on Wednesday. Speaking at abriefing for analysts and investors, Greg Foran said the gap inpricing between Wal-Mart and its competitors in some markets was"too small".

** COHERUS BIOSCIENCES INC, $27.67, -9.52 pct

The biotech company priced its offering of 4.1 millionshares at $29 each, a 5 pct discount to stock's Tuesday close.The upsized $120 million offering represents 12 percent of thecompany's outstanding shares as of Feb. 28.

** AMERICAN AIRLINES GROUP INC, $50.3101, -4.68 pct

** DELTA AIR LINES INC, $43, -4.36 pct

** UNITED CONTINENTAL HOLDINGS INC, $64.4, -4.24 pct

Analysts at Deutsche Bank cut ratings on airlines' stocks to"hold" from "buy", saying they expect disappointing earningsgrowth from international markets. The combination of a strongUS dollar, greater-than-expected capacity increases by non-USairlines, and decelerating global GDP growth are likely tofurther pressure Deutsche Bank's forecast (from internationalmarkets) for 2015, analysts write in a note.

** MACERICH CO, $79.63, -5.57 pct

** SIMON PROPERTY GROUP INC, $197.54, +0.97 pct

Simon Property Group scrapped its attempt to buy Macerichafter the smaller shopping mall owner rejected its sweetenedoffer of $23.2 billion including debt. Macerich Chief ExecutiveArthur Coppola said the company's board concluded that the offerdid not reflect the full value of the company.

** GLAXOSMITHKLINE PLC, $46.58, +0.93 pct

** MERCK & CO INC, $56.76, -1.25 pct

Cowen & Co analysts said the drugmaker's vaccine totreat shingles may be more effective than Merck's. Glaxo'svaccine HZ/su should be well positioned to capture market sharefrom Merck's Zostavax if final data from a late-stage studyshows HZ/su has better efficacy while treating older patients,analysts said.

** NUVASIVE INC, $45.15, -1.83 pct

The medical device maker said its chief executive of 16years Alex Lukianov had resigned after an independentinvestigation showed he had not complied with the medical devicemaker's expense reimbursement and personnel policies. Theamounts involved appeared immaterial to financial results, thecompany said. NuVasive has appointed board member Greg Lucier asinterim CEO.

** EVERYWARE GLOBAL INC, $0.223, -81.42 pct

The marketer of tabletop and food preparation products saidit expects to file for prepackaged bankruptcy that will give itssecured lenders control of the company after it emerges from thebankruptcy. EveryWare said it expects to file for a prepackagedChapter 11 bankruptcy in the U.S. Bankruptcy Court for theDistrict of Delaware and expects to emerge from bankruptcywithin 60-75 days.

** DYAX CORP, $25, +49.21 pct

The drug developer said its experimental drug, DX-2930, toprevent hereditary angioedema attacks, was found effective in anearly stage study. The drug was also assigned fast-track statusby the U.S. FDA. All seven analysts covering the stock raisedprice targets, saying the strong results show the drug couldeclipse the current standard-of-care preventive treatment forHAE.

** UTI WORLDWIDE INC, $10.3425, -15.91 pct

The logistics company reported a wider-than-expectedfourth-quarter loss, hurt by lower air and ocean freightforwarding yields and lower volumes in freight forwarding. Thecompany also cuts its 2016 adjusted EBITDA forecast to $125million-$150 million from $190 million-$210 million and saidrevenue would be hurt by the strengthening of the dollar. MorganStanley cuts price target by $2.50 to $10, now the lowest onWall Street.

** SYNNEX CORP, $72.95, -5.57 pct

The hardware distributor forecast second-quarter revenue andadjusted profit below analysts' average estimates, sayingrevenue is expected to be lowered by about $130 million due tothe stronger dollar. The company on Tuesday also reportedlower-than-expected first-quarter profit and revenue.

** SEARS HOLDINGS CORP, $42.88, +3.62 pct

The struggling retailer plans to raise more than $2.5billion from shareholders by offering rights to buy shares in areal estate investment trust that will hold some of its stores.The REIT, Seritage Growth Properties, will buy and lease backabout 254 Sears and Kmart stores, Sears said on Wednesday. Searsalso said it would sell 12 stores to a joint venture it wasforming with No.2 U.S. mall operator General Growth PropertiesInc, in which the companies would hold 50 percent each.

** VOLTARI CORP, $2.6701, +164.37 pct

Billionaire investor Carl Icahn raises his stake in thedigital advertising company to 52.3 percent. Icahn bought about4 million Voltari shares at $1.36 each via a rights offering.

** MYLAN NV, $58.4, -1.60 pct

** ABBOTT LABORATORIES, $45.71, -1.34 pct

The generic drug maker priced an offering of 35 millionshares at $58.35 per share, a discount of about 2 percent to thestock's Tuesday close. All shares in the offering are to be soldby Abbott Laboratories for net proceeds of about $1.99 billion.

** CARPENTER TECHNOLOGY CORP, $36.14, -7.05 pct

The alloys maker said on Tuesday that it will cut about 10percent of its salaried workforce, or 200 jobs, to reduce costsamid weak oil and gas prices. The company will also cut about 60outsourced positions.

** SAREPTA THERAPEUTICS INC, $14.15, +6.55 pct

The drug developer appointed Chief Medical Officer EdwardKaye as interim CEO, replacing Christopher Garabedian, whoresigned. Sarepta is also expected to meet with the FDA over thecoming weeks to finalize an application to market its lead drug,eteplirsen, which is designed to attack the underlying cause ofDuchenne muscular dystrophy (DMD), a progressive muscle wastingdisorder.

** CYTOSORBENTS CORP, $10.4201, -21.00 pct

The medical device maker said it expects first-quarter salesto be slightly lower than they were in the fourth-quarter asrestructuring of its direct sales force created a significantgap in sales coverage and resulted in lower direct sales.

** CHESAPEAKE ENERGY CORP, $14.44, +1.98 pct

The oil and gas producer's Chairman Dunham Archie bought 1million shares at $13.98 per share on March 27, according to aregulatory filing on Tuesday. The purchase price represents a1.3 percent discount to the stock's Tuesday close. After thepurchase, Archie holds 2.6 million shares of the company. (Compiled by Ramkumar Iyer in Bengaluru; Editing by SimonJennings)

More News
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
13 Feb 2024 07:45

LONDON BRIEFING: "Record" Tui quarter; Ultimate Products eyes payouts

(Alliance News) - London's FTSE 100 is to open ever-so-slightly lower on Tuesday, with trade set to be nervy ahead of the afternoon's US inflation data.

Read more
12 Feb 2024 17:11

London close: Stocks finish higher after very quiet Monday

(Sharecast News) - London markets managed modest gains by the close of a subdued trading session on Monday, with no significant corporate or economic catalysts driving movements.

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.